Galderma R&D
Clinical trials sponsored by Galderma R&D, explained in plain language.
Dermatology-focused pharmaceutical company developing skin treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Sculptra shots aim to smooth cheek wrinkles in new study Results expected Sep 2026 (estimated)
- New drug shows promise for chronic itch in Long-Term trial Results expected Oct 2026 (estimated)
- Menopausal Women's skin changes under microscope in new study Results expected Nov 2026 (estimated)
- New Real-World study tests nemolizumab for persistent eczema itch Results expected Nov 2026 (estimated)
- New drug targets mysterious chronic itch Results expected Dec 2026 (estimated)
-
New acne cream shows promise in chinese trial
Symptom relief OngoingThis study tests a cream called trifarotene on Chinese people aged 9 and older with moderate acne on the face and upper body. About 561 participants will apply the cream or a placebo daily for 12 weeks. The goal is to see if the cream reduces acne lesions and improves skin appear…
Phase 3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
New gel injections aim to smooth cheek wrinkles
Symptom relief OngoingThis pilot study will test the safety and effectiveness of two injectable gels, GP0122 and GP0124, for reducing lines and wrinkles in the cheek area. About 60 adults with moderate to severe cheek wrinkles will receive the treatment and be followed for 12 months. The main goal is …
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets mysterious chronic itch
Symptom relief OngoingThis Phase 2 study tests a drug called nemolizumab in 50 adults with chronic itching that has no known cause. The goal is to see how the drug works in the body and whether it can reduce itching over 16 weeks. Participants receive either nemolizumab or a placebo injection.
Phase 2 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Can a filler boost your Skin's look? new study tests restylane
Symptom relief OngoingThis study tests if Restylane Skinboosters Vital Lidocaine can improve facial skin quality, like reducing fine lines. About 171 Chinese adults will either get the treatment or no treatment. The goal is to see if the treatment makes a visible difference in skin smoothness.
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for chronic itch in Long-Term trial
Symptom relief OngoingThis study looks at the long-term safety of nemolizumab in 500 adults with prurigo nodularis, a condition causing severe itching and skin bumps. Participants must have taken nemolizumab in a previous study. The main goal is to track side effects over time, while also checking if …
Phase 3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC